C
NexgenRx Inc.
NEGXF
$0.20
$0.00351.78%
C
Hold
12/20/2024Upgraded
NexgenRx Inc. (NEGXF) was upgraded to C from C- on 12/20/2024 due to an increase in the volatility index.
NexgenRx Inc. (NEGXF) was upgraded to C from C- on 12/20/2024 due to an increase in the volatility index.
C
Hold
12/4/2024Downgrade
NexgenRx Inc. (NEGXF) was downgraded to C- from C on 12/4/2024 due to a decline in the volatility index and dividend index.
NexgenRx Inc. (NEGXF) was downgraded to C- from C on 12/4/2024 due to a decline in the volatility index and dividend index.
C
Hold
9/25/2024Upgraded
NexgenRx Inc. (NEGXF) was upgraded to C from C- on 9/25/2024 due to a substantial increase in the growth index, volatility index and efficiency index. Operating cash flow increased 284.56% from -$390.5 to $720.7.
NexgenRx Inc. (NEGXF) was upgraded to C from C- on 9/25/2024 due to a substantial increase in the growth index, volatility index and efficiency index. Operating cash flow increased 284.56% from -$390.5 to $720.7.
C
Hold
4/11/2024Upgraded
NexgenRx Inc. (NEGXF) was upgraded to C- from D+ on 4/11/2024 due to an increase in the volatility index, dividend index and efficiency index.
NexgenRx Inc. (NEGXF) was upgraded to C- from D+ on 4/11/2024 due to an increase in the volatility index, dividend index and efficiency index.
D
Sell
11/28/2023Downgrade
NexgenRx Inc. (NEGXF) was downgraded to D+ from C- on 11/28/2023 due to a decline in the efficiency index, volatility index and growth index. EBIT declined 1,436.51% from $6.3 to -$84.2, net income declined 1,423.44% from -$6.4 to -$97.5, and earnings per share declined from -$0.0001 to -$0.0015.
NexgenRx Inc. (NEGXF) was downgraded to D+ from C- on 11/28/2023 due to a decline in the efficiency index, volatility index and growth index. EBIT declined 1,436.51% from $6.3 to -$84.2, net income declined 1,423.44% from -$6.4 to -$97.5, and earnings per share declined from -$0.0001 to -$0.0015.
C
Hold
8/1/2023Upgraded
NexgenRx Inc. (NEGXF) was upgraded to C- from D+ on 8/1/2023 due to an increase in the volatility index, growth index and solvency index. EBIT increased 265.06% from -$95.3 to $157.3, earnings per share increased from -$0.0039 to $0.002, and debt to equity declined from 0.01 to 0.
NexgenRx Inc. (NEGXF) was upgraded to C- from D+ on 8/1/2023 due to an increase in the volatility index, growth index and solvency index. EBIT increased 265.06% from -$95.3 to $157.3, earnings per share increased from -$0.0039 to $0.002, and debt to equity declined from 0.01 to 0.
D
Sell
4/10/2023Downgrade
NexgenRx Inc. (NEGXF) was downgraded to D+ from C on 4/10/2023 due to a significant decline in the valuation index, dividend index and growth index. Earnings per share declined from -$0.0008 to -$0.0039, EBIT declined 349.53% from -$21.2 to -$95.3, and operating cash flow declined 136.05% from $988.6 to -$356.4.
NexgenRx Inc. (NEGXF) was downgraded to D+ from C on 4/10/2023 due to a significant decline in the valuation index, dividend index and growth index. Earnings per share declined from -$0.0008 to -$0.0039, EBIT declined 349.53% from -$21.2 to -$95.3, and operating cash flow declined 136.05% from $988.6 to -$356.4.
C
Hold
3/3/2023Upgraded
NexgenRx Inc. (NEGXF) was upgraded to C from C- on 3/3/2023 due to a major increase in the total return index.
NexgenRx Inc. (NEGXF) was upgraded to C from C- on 3/3/2023 due to a major increase in the total return index.
C
Hold
12/6/2022Upgraded
NexgenRx Inc. (NEGXF) was upgraded to C- from D+ on 12/6/2022 due to an increase in the volatility index.
NexgenRx Inc. (NEGXF) was upgraded to C- from D+ on 12/6/2022 due to an increase in the volatility index.
D
Sell
12/1/2022Upgraded
NexgenRx Inc. (NEGXF) was upgraded to D+ from D on 12/1/2022 due to an increase in the dividend index, efficiency index and volatility index.
NexgenRx Inc. (NEGXF) was upgraded to D+ from D on 12/1/2022 due to an increase in the dividend index, efficiency index and volatility index.
D
Sell
11/21/2022Downgrade
NexgenRx Inc. (NEGXF) was downgraded to D from D+ on 11/21/2022 due to a large decline in the total return index and volatility index.
NexgenRx Inc. (NEGXF) was downgraded to D from D+ on 11/21/2022 due to a large decline in the total return index and volatility index.
D
Sell
9/30/2022Downgrade
NexgenRx Inc. (NEGXF) was downgraded to D+ from C on 9/30/2022 due to a significant decline in the growth index, volatility index and total return index. Earnings per share declined from $0.0039 to -$0.0004, EBIT declined 87.6% from $312 to $38.7, and total revenue declined 2.63% from $2.51M to $2.44M.
NexgenRx Inc. (NEGXF) was downgraded to D+ from C on 9/30/2022 due to a significant decline in the growth index, volatility index and total return index. Earnings per share declined from $0.0039 to -$0.0004, EBIT declined 87.6% from $312 to $38.7, and total revenue declined 2.63% from $2.51M to $2.44M.
C
Hold
12/16/2021Upgraded
NexgenRx Inc. (NEGXF) was upgraded to C from C- on 12/16/2021 due to an increase in the total return index.
NexgenRx Inc. (NEGXF) was upgraded to C from C- on 12/16/2021 due to an increase in the total return index.
C
Hold
12/1/2021Downgrade
NexgenRx Inc. (NEGXF) was downgraded to C- from C on 12/1/2021 due to a decline in the volatility index.
NexgenRx Inc. (NEGXF) was downgraded to C- from C on 12/1/2021 due to a decline in the volatility index.
C
Hold
12/31/2020Upgraded
NexgenRx Inc. (NEGXF) was upgraded to C from C- on 12/31/2020 due to an increase in the volatility index and total return index.
NexgenRx Inc. (NEGXF) was upgraded to C from C- on 12/31/2020 due to an increase in the volatility index and total return index.
C
Hold
12/18/2020Upgraded
NexgenRx Inc. (NEGXF) was upgraded to C- from D+ on 12/18/2020 due to an increase in the volatility index and total return index.
NexgenRx Inc. (NEGXF) was upgraded to C- from D+ on 12/18/2020 due to an increase in the volatility index and total return index.
D
Sell
12/9/2020Upgraded
NexgenRx Inc. (NEGXF) was upgraded to D+ from D on 12/9/2020 due to a significant increase in the valuation index, growth index and efficiency index. Total revenue increased 14.63% from $1.74M to $1.99M, net income increased 10.64% from $345.9 to $382.7, and EBIT increased 9.32% from $395.8 to $432.7.
NexgenRx Inc. (NEGXF) was upgraded to D+ from D on 12/9/2020 due to a significant increase in the valuation index, growth index and efficiency index. Total revenue increased 14.63% from $1.74M to $1.99M, net income increased 10.64% from $345.9 to $382.7, and EBIT increased 9.32% from $395.8 to $432.7.
D
Sell
1/27/2020Upgraded
NexgenRx Inc. (NEGXF) was upgraded to D from E on 1/27/2020 due to an increase in the efficiency index, growth index and total return index. Operating cash flow increased 17.05% from $180.1 to $210.8.
NexgenRx Inc. (NEGXF) was upgraded to D from E on 1/27/2020 due to an increase in the efficiency index, growth index and total return index. Operating cash flow increased 17.05% from $180.1 to $210.8.
E
Sell
12/3/2018Downgrade
NexgenRx Inc. (NEGXF) was downgraded to E from D- on 12/3/2018 due to a decline in the solvency index. Debt to equity increased from 0.28 to 1.88.
NexgenRx Inc. (NEGXF) was downgraded to E from D- on 12/3/2018 due to a decline in the solvency index. Debt to equity increased from 0.28 to 1.88.
D
Sell
9/4/2018Upgraded
NexgenRx Inc. (NEGXF) was upgraded to D- from E+ on 9/4/2018 due to an increase in the valuation index.
NexgenRx Inc. (NEGXF) was upgraded to D- from E+ on 9/4/2018 due to an increase in the valuation index.
E
Sell
6/5/2018Upgraded
NexgenRx Inc. (NEGXF) was upgraded to E+ from E on 6/5/2018 due to a large increase in the total return index, solvency index and valuation index.
NexgenRx Inc. (NEGXF) was upgraded to E+ from E on 6/5/2018 due to a large increase in the total return index, solvency index and valuation index.
E
Sell
3/16/2018None
NexgenRx Inc. (NEGXF) was downgraded to E from U on 03/16/2018.
NexgenRx Inc. (NEGXF) was downgraded to E from U on 03/16/2018.
OTC PK
12/23/2024 10:06AM Eastern
Quotes delayed
